LumiraDx Partners with AstraZeneca & Everton in the Community to Set Up England’s First Heart & Lung Screening Hub
21 October 2023 - 9:34AM
LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care
diagnostics company, is pleased to announce a strategic
collaboration with AstraZeneca and Everton in the Community to set
up England’s first community-based heart and lung screening hub,
set to go live in November.
The official charity of Everton Football Club will run this
novel screening hub from the recently opened People’s Place. The
hub will provide the Merseyside community with access to the latest
technologies and specialist input from a multidisciplinary team of
primary care, heart, and lung specialists to focus on early
diagnosis and early treatment for chronic breathlessness in a
walk-in setting.
Michael Salla, Deputy CEO for Everton in the Community, said,
“We’re delighted to be launching this project, which is the first
screening service of its kind for heart failure, COPD and asthma in
England. It will use next generation diagnostics that don’t require
phlebotomy, while also using artificial intelligence to help detect
heart failure and prevent premature mortality alongside reducing
the complications of these conditions due to the early detection.
We can’t thank AstraZeneca enough for their support to make this
happen.”
The heart and lung screening hub will work to raise awareness of
medical conditions which cause chronic breathlessness, offer
screenings for heart failure, chronic obstructive pulmonary disease
(COPD) and other chronic conditions which are common in the local
population as well as offer lifestyle reviews and advice.
David Walton, Chief Commercial Officer at LumiraDx points out,
“A full blood draw can be daunting for patients, so the use of a
simple fingerstick sample for our NT-proBNP test greatly broadens
access to heart health checks within the community. By diagnosing
heart failure faster, we aim to make a positive impact on patient
outcomes, which then translates into positive economic outcomes for
the NHS.”
Dr. Ed Piper, Medical & Scientific Affairs Director at
AstraZeneca UK, comments, “AstraZeneca is delighted to support this
innovative screening hub in the heart of Merseyside with grant
funding. Prompt identification of the underlying cause of chronic
breathlessness allows appropriate, tailored intervention which
reduces symptoms and improves long term outcomes. The convenience
of the hub in The People’s Place will help ensure that broad, rapid
access to essential diagnostics is embedded in the community.”
The programme will also work closely with Pumping Marvellous,
the UK’s patient-led heart failure charity, who offer vital support
to help people live well with heart failure. Nick Hartshorne-Evans,
founder and CEO of the charity, commented, “Patients are often
initially misdiagnosed or diagnosed late. Patients tell us in our
communities that catching their diagnosis quickly and efficiently
means they know what they are dealing with. This improves their
mental health and ensures they are not suffering from anxiety
around the unknown whilst improving access to guideline standard
care and treatments.”
In addition, LumiraDx continues to participate in a similar
initiative – the "Your Heart Matters" Bus – with strategic
collaborator Medtronic. The first event was held over two days in
Yorkshire in February 2023 with a follow-up event held in
Manchester in July 2023. A third event is scheduled for November
2023 in Leeds.
The strategic partnership with AstraZeneca and Everton in the
Community will also work closely with Liverpool University
Hospitals NHS Foundation Trust and next generation medical
technology providers Lenus Health, Us2.ai and ArtiQ. It is yet
another example of how LumiraDx continues to drive for improved
patient outcomes by broadening access to critical diagnostic tests
and ultimately transforming how patient care is delivered within
the community.
About LumiraDx
LumiraDx Limited (Nasdaq: LMDX) is a next-generation point of
care diagnostics company that is transforming community-based
healthcare. Its actively controlled microfluidic technology
provides fast, high performance and accessible diagnostic solutions
wherever the patient is for nearly any testing scenario, creating
unique testing options at the point of need.
The company offers a broad menu of lab comparable tests on a
single portable Platform, with a target of > 30 assays on the
market and in various stages of development, covering infectious
disease, cardiovascular disease, diabetes, and coagulation
disorders. The company also supports high-complexity laboratory
testing in an accessible high-throughput format to leverage current
molecular laboratory operations.
Founded in 2014 and based in the UK, LumiraDx's diagnostic
testing solutions are being deployed globally by governments and
leading healthcare institutions across laboratories, urgent care,
physician offices, pharmacies, schools, and workplaces to help
screen, diagnose, and monitor wellness as well as disease. More
information on LumiraDx is available at www.lumiradx.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995, including statements regarding the benefits and performance
of the LumiraDx NT-proBNP test. These statements involve risks,
uncertainties and other factors that may cause actual results,
levels of activity, performance or achievements to be materially
different from the information expressed or implied by these
forward-looking statements, including, among others, general
economic, political and business conditions; changes in interest
rates, inflation rates and global and domestic market conditions;
the effect of COVID-19 on LumiraDx's business and financial
results; obtaining or maintaining regulatory approval,
authorization or clearance for our tests; and those factors
discussed under the header "Risk Factors" in our Annual Report on
Form 20-F for the year ended December 31, 2022, which was filed
with the Securities and Exchange Commission, or SEC, on May 1,
2023, and in other filings that we make with the SEC. Although
LumiraDx believes that it has a reasonable basis for each
forward-looking statement contained in this press release, LumiraDx
cautions you that these statements are based on a combination of
facts and factors currently known by it and its projections of the
future, about which it cannot be certain. LumiraDx undertakes no
obligation to update or revise the information contained in this
press release, whether as a result of new information, future
events or circumstances or otherwise.
* Not all tests are available in all countries and regions. For
additional detail on product availability please visit
www.lumiradx.com.
Media Contact:
investors@lumiradx.com
LumiraDx (NASDAQ:LMDX)
Historical Stock Chart
From Apr 2024 to May 2024
LumiraDx (NASDAQ:LMDX)
Historical Stock Chart
From May 2023 to May 2024